Regeneron Hits A New Record High On The Approval That ‘Could Not Come Soon Enough’
Investor's Business DailyShares of REGN stock jumped Monday after the FDA approved Regeneron Pharmaceuticals’ high-dose Eylea following a delay this summer.
The post Regeneron Hits A New Record High On The Approval That 'Could Not Come Soon Enough' appeared first on …